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A new class of prophylactic metallo-antibiotic
possessing potent anti-cancer and anti-microbial
properties†
Ziga Ude,a Kevin Kavanagh,b Brendan Twamley,c Milan Pour, d
Nicholas Gathergood, e Andrew Kellett *f and Celine J. Marmion *a
Immunocompromised cancer patients are often at high risk of developing infections. Standard infection
control measures are required to prevent the onset of infection but, under some circumstances, anti-
microbial prophylaxis is necessary. We have developed a family of innovative metallo-antibiotics of
general formula [Cu(N,N)(CipA)Cl] where N,N represents a phenanthrene ligand and CipA stands for a
derivative of the clinically used fluoroquinolone antibiotic ciprofloxacin. The X-ray crystal structure of one
member from this family, [Cu(phen)(CipA)Cl] (where phen is 1,10-phenanthroline), is also reported. These
complexes combine into one drug entity a Cu-N,N-framework with DNA binding and DNA oxidant pro-
perties and an antibiotic derivative with known anti-proliferative and anti-microbial activities. The com-
plexes were all found to exhibit excellent DNA recognition with binding affinity of lead agents in the order
of ∼107 M(bp)−1. Biophysical studies involving calf thymus DNA indicate the complexes intercalate or
semi-intercalate DNA via the minor groove. All complexes exhibited excellent nuclease activity with DNA
strand scission being mediated predominantly via superoxide and hydroxyl radicals. The complexes were
found to have promising anti-proliferative effects against a human breast adenocarcinoma cell line
(MCF-7) and a human prostate carcinoma cell line (DU145) with low micromolar and, in some cases,
nanomolar cytotoxicities observed. Selective targeting of Gram positive bacteria was also identified by this
complex class with one lead compound having an order of magnitude greater potency against
Methicillin-resistant S. aureus (MRSA) as compared to the CipA ligand. Importantly, from a clinical stand
point, these complexes were also found to be well tolerated in an in vivo Galleria mellonella larvae model,
which has both functional and structural similarities to that of the innate immune system of mammals.
1. Introduction
DNA represents an important target for many cancer thera-
peutics. For example, platinum drugs, which are amongst the
most widely utilised therapeutics in cancer treatment regi-
mens, irreversibly bind to DNA nucleobases.1 This results in
the formation of DNA lesions, which ultimately leads to
tumour cell apoptosis or programmed cell death.1 Despite
their enormous clinical success, many platinum drugs have
shortcomings, not least dose-limiting toxic side effects and
acquired or intrinsic drug resistance.1,2 A number of research
strategies are being actively pursued in an attempt to overcome
these drawbacks. These include the exploitation of nano-
technologies, which can selectively deliver platinum(II) pay-
loads to tumours.2 An alternative strategy is to develop non-
platinum based drugs with a mechanism of action and toxicity
profile different to classical platinum therapies. In this regard,
copper complexes are being actively explored on the assump-
tion that complexes incorporating endogenous metal ions
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such as copper(II) may be less toxic to normal cells and may
thus give rise to less toxic side effects.3 Copper complexes may
also have a mechanism of action and therefore cytotoxicity
profile different to platinum-based drugs and may thus also
potentially evade the chemoresistance related to recurrent
platinum drug treatments. It is also noteworthy that known
platinum reserves will be depleted within ca. 50 years.4 Cancer
therapeutics based on relatively more abundant metals (e.g.
copper) are therefore also of great interest.
The majority of the copper(II) complexes reported to-date as
potential anti-cancer agents, target DNA. Four modes of DNA
binding have been reported; (i) electrostatic, (ii) groove
binding, (iii) intercalation, and/or (iv) direct binding to DNA
nucleobases.3b Copper complexes can also cleave DNA strands
either via hydrolysis of the phosphodiester backbone or by an
oxidative mechanism whereby H-atom abstraction from the
deoxyribose ring of DNA occurs.5 Such oxidative DNA cleavage
is predominantly mediated via the formation of reactive
oxygen species (ROS) generated either by a redox- or photo-
induced process3a,b although there are some examples of
copper complexes acting as self-activating DNA nuclease
agents.6 Sigman et al. discovered the artificial chemical nucle-
ase properties of copper(I) bis-1,10-phenanthroline systems.
The Cu-bis-phenanthroline complex, [Cu(phen)2]
2+ (where
phen is 1,10-phenathroline) Fig. 1 (1), for example, is capable
of inducing oxidative DNA damage in the presence of a reduc-
tant (and oxidant, e.g. O2) through free radical oxidation of
deoxyribose.7 This complex, however, binds without specificity,
to a number of different targets including not only double
stranded DNA but also protein biomolecules.3c In an effort to
enhance DNA binding and intercalation, Kellett et al. rationally
designed and developed a series of cationic phenazine functiona-
lised copper(II)-phen complexes of formula [Cu(DPQ)(phen)]
(NO3)2 (2), [Cu(DPPZ)(phen)](NO3)2 (3), and [Cu(DPPN)(phen)]
(NO3)2 (4) (where DPQ = dipyridoquinoxaline, DPPZ = dipyrido-
phenazine, and DPPN = benzo[i]dipyridophenazine), Fig. 1.8
By systematically extending the phenazine ligand from phen to
DPQ to DPPZ, the resulting complexes could not only influ-
ence DNA recognition but also induce oxidative DNA degra-
dation. In fact, the calf thymus DNA (ctDNA) binding con-
stants (∼107 M(bp)−1) for these complexes are amongst the
highest currently reported for copper(II)-phenanthrene
systems. The complexes were also highly cytotoxic toward a cis-
platin-resistant ovarian cancer line, comparable to that of the
clinical oxidative DNA-damaging drug doxorubicin
(Adriamycin).8
Inspired by the potential inherent in the aforementioned
Cu-phenazine derivatives (1–4) along with more recent
advances in this field,9 we sought to exploit this Cu-phenazine
framework as a platform in which to add additional thera-
peutic moieties. We specifically sought to introduce an anti-
microbial agent on the basis that cancer patients, particularly
those who sustain neutropenia (where the white blood cell
count is lower than normal) during the course of their disease,
are often highly predisposed to infections.10 Therapy-related
myelosuppression and immune defects inherent in the cancer
disease process are also notable risk factors for infection.11
The use of central venous catheters (CVCs) for the adminis-
tration of chemotherapeutic agents can also pose significant
risk. Bacteraemia rates in cancer patients, resulting from
central line associated bloodstream infections (CLABSIs),
range from 11–38%.12 Mortality rates of 9.6%, arising from
CLABSI, have been reported in paediatric oncology patients.13
Prophylactic anti-microbial therapies may be an option in tar-
geted cancer patients or cancer populations being treated at
institutions in which high rates of CLABSIs, despite infection
control, are observed.12 In addition, peri/post-operative anti-
biotic prophylaxis (POABP) has become standard practice in an
attempt to prevent surgical site infections in head and neck
cancer patients following microvascular reconstruction.14
Quinolones, and especially fluoroquinolones, are widely uti-
lised in human medicine to treat both Gram-negative and Gram-
positive bacterial infections.15 Topoisomerases—enzymes that
mediate the topical changes in DNA during a range of processes
are considered to be one of the main targets of quinolones.15
Several copper(II) complexes incorporating fluoroquinolones
have been reported including a moxifloxacin (Moxi) derivative
[Cu(Moxi)2(H2O)2],
16 and a Hpr-norfloxacin (Hpr-norf) derivative
[Cu(Hpr-norf)(bpy)Cl].17 While these complexes exhibited anti-
cancer activity, to the best to our knowledge, their anti-microbial
properties were not investigated. Ciprofloxacin (Cip), Fig. 2 (5), a
member of the fluoroquinolone family, is particularly important
since it is classified as an essential medicine by the World
Health Organization.18 A copper(II) complex incorporating two
Cip ligands, [Cu(Cip)2(ClO4)2], has been reported.
19 It exhibited
higher potency as an anti-bacterial against two strains of the
Gram positive bacterium Staphylococcus aureus (S. aureus) when
compared to Cip itself. Interestingly, and in contrast to Cip
alone, the complex was found to be more damaging against
stationary phase bacteria, a property which may be attractive for
the treatment of chronic or device-related infections (such as
catheter infections) which involve slowly metabolising bacteria
in biofilm mode. The X-ray crystal structure of [Cu(phen)(Cip)Cl]
Cl has also been reported but its anti-cancer and anti-microbial
properties were not evaluated.20
While the anti-microbial properties of Cip are well known,
Azema et al. developed a library of Cip derivatives with a view
Fig. 1 Molecular structures of ternary copper(II) complexes incorporat-
ing 1,10-phenanthroline (phen) and phenanthrene (DPQ; DPPZ; or
DPPN) ligands.
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to assessing their anti-cancer potential.21 Of these, the 7-(4-
(decanoyl)piperazin-1-yl) derivative CipA, Fig. 2 (6), was par-
ticularly cytotoxic (in the low µM range) against a range of
tumour cell lines, indeed much more so than Cip itself. This
derivative was also non-toxic in an in vivo xenograft mouse
model. To further expand this class of compounds, we recently
reported a ruthenium(II)–arene complex incorporating this Cip
derivative, Fig. 2 (7). This complex possessed potent in vitro
cytotoxicity against a small range of tumour cell lines but only
exhibited moderate anti-microbial activity.22
Given that copper(II) complexes have demonstrated signifi-
cant potential as anti-microbial agents,23 we sought to
combine into one drug molecule, the Cu-phenazine framework
with the Cip derivative CipA (6) with the expectation of gener-
ating a multi-modal therapeutic possessing both potent
cytotoxicity and anti-microbial properties, Fig. 2.
In this contribution, we report the synthesis and biological
evaluation of the first examples of a family of [Cu(N,N)(CipA)
Cl] derivatives, herein referred to as Cu-N,N-CipA, in which N,
N is phen (8), DPQ (9) or DPPZ (10). Through structure–activity
relationship studies, we sought to ascertain whether we could
modulate or enhance the anti-microbial activity of this Cip
derivative via complexation to a Cu-phenazine framework
whilst retaining or enhancing its cytotoxic potential. We
specifically investigated the ability of our Cu-N,N-CipA com-
plexes to induce DNA damage via intercalation and/or ROS-
mediated DNA cleavage. Their ability to inhibit topoisomerase
I was also investigated given that these enzymes are one of the
main targets of fluoroquinolones. Cytotoxicities of 8–10
were assessed against a human breast adenocarcinoma cell
line (MCF-7) and a human prostate carcinoma cell line
(DU145). The complexes, 8–10, were also screened for anti-
microbial and anti-fungal activity. Furthermore, a preliminary
in vivo study was undertaken using a Galleria mellonella
(G. mellonella) larvae model to assess their toxicity profile.
A summary of these findings is presented herein.
2. Results and discussion
2.1. Synthesis and characterisation of the Cu-N,N-CipA
complexes
The ligands phendione, DPQ and DPPZ8 and CipA21 were syn-
thesised according to previously published methods. Schiff-
base condensation of phendione with either ethylenediamine
or 1,2-phenylenediamine afforded the phenazine ligands DPQ
and DPPZ respectively. Treatment of an aqueous solution of
CuCl2·2H2O with one molar equivalent of phen, DPQ or DPPZ
in hot ethanol, followed by the addition of one molar equi-
valent of a basic methanolic solution of CipA, afforded the
complexes as green solids in excellent purity and good yield.
Turquoise crystals of [Cu(phen)(CipA-H)Cl], suitable for X-ray
structure determination, were isolated. The asymmetric unit
consists of a [Cu(phen)(CipA-H)Cl] unit and one water and one
methanol molecule, Fig. 3. The Cu2+ ion is coordinated by two
CipA O atoms and two phen N atoms in the equatorial plane,
and by a Cl ion in the axial position. It adopts a slightly dis-
torted square pyramidal geometry, with an O15–Cu–O20 angle
of 93.18(15)° and a N1–Cu–N12 angle of 81.11(17)°. All bond
lengths and angles are in agreement with literature values.24
For example, distances between Cu2+ and the CipA O’s are
1.909(4) Å and 1.944(3) Å, respectively, consistent with litera-
ture reports.24 The Cu1–Cl1 bond length is 2.4757(13) Å, again
within the expected range. Metal-to-ligand distances are also
similar to those found in related compounds where Cu2+ ion is
coordinated to cinoxacin, nalidixic acid,25 and to Cip.20 The
complex is almost planar, with the exception of the piperazine
ring, which has a slightly affected chair conformation due to
Fig. 2 Chemical structures of Cip (5), CipA (6) and [Ru(η6-p-cym)(CipA-H)Cl] (7) and of the Cu-N,N-(CipA-H)Cl complexes (8–10).
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the presence of the aliphatic chain, and the cyclopropyl ring,
which makes a dihedral angle of 38.63(1)° with the Cu(phen)
(CipA-H) plane. [Cu(phen)(CipA-H)Cl] co-crystallised with a
mixture of water and methanol (one molecule of each). The
packing diagram of [Cu(phen)(CipA-H)Cl] suggests molecules of
[Cu(phen)(CipA-H)Cl] in each cell unit being connected to each
other via hydrogen bonds, where molecules of water form strong
hydrogen bonds with the carbonyl O’s of CipA (d(O16–Owater) of
2.754(6) Å and the Cl’s (d(Cl1–Owater) of 3.134(4) Å.
ESI mass spectra of all complexes (8–10) (ESI – SI†) revealed
m/z peaks corresponding to [Cu(N,N)(CipA-H)]
+ as expected. IR
spectroscopy also confirmed each compound to contain
vibrational peaks characteristic of coordinated aromatic imines
and carboxylate ligands and consistent with complexation to
the copper(II) ion via the pyridone O and deprotonated carboxy-
late O26 with X-ray crystallographic analysis of [Cu(phen)
(CipA-H)Cl] confirming this mode of binding (see Fig. 3).
2.2. In vitro anti-proliferative activity
To investigate the in vitro cytotoxic properties of the Cu-N,
N-CipA complexes, concentrations which induced 50% inhi-
bition of cellular proliferation (IC50) across two cancerous cell
lines at 24 and 72 h time points were first determined via the
colorimetric MTT assay.27 Sigmoidal dose–response curves
were plotted and concentrations which inhibited 50% cellular
proliferation (IC50 values) were determined via statistical ana-
lysis at the 95% confidence interval. The human breast adeno-
carcinoma cell line (MCF-7) and the human prostate carci-
noma cell line (DU145) were chosen on the basis they are
amongst the most common cancer diagnoses (according to
estimated new cases in 2018) as listed by the National Cancer
Institute.28 MCF-7 are also an example of slow-growing cells as
well as being poorly responsive to some copper(II) complexes
described in the literature.29 Furthermore, the DU145 cell line
was also selected because these cells possess a mutant
p53 gene30 and modifications in its expression can lead to
transcriptional activation of p21 and p73, which results in
apoptosis. Mutations in the TP53 gene which encodes for the
p53 tumour suppressor, are the most commonplace alterations
in human cancer. Mutant p53 cannot bind DNA in an effective
way, leading to the p21 protein not being available to act as
the ‘stop signal’ for cell division.31 According to the
International Agency for Research on Cancer there appears to
be more than 26 000 somatic mutations of p53.32 As a repre-
sentative control, we compared the cytotoxicity of our com-
plexes to that of doxorubicin (US trade name Adriamycin) due
to its known DNA-damaging properties and an ability to
inhibit topoisomerase II.33
As reported in the literature, doxorubicin shows high cyto-
toxicity after 24 h against MCF-7 and DU145 cell lines with
IC50 values of 1.44 ± 0.28 and 0.15 ± 0.02 µM respectively,
Table 1.9a Its cytotoxicity is enhanced following an additional
48 h of incubation (72 h in total) with IC50 values of 0.94 ±
0.19 and <1.25 µM against MCF-7 and DU145, respectively.
After 24 h drug treatment, the complexes showed excellent
in vitro cytotoxicity with low µM IC50 values observed ranging
from 2.12–7.43 µM against MCF-7 and 3.27–5.59 µM against
DU145 cells, Table 1. The order of activity after 24 h exposure
in the MCF-7 cell line was Cu-DPPZ-CipA > Cu-DPQ-CipA > Cu-
phen-CipA. In DU145 cells, the most active complex after 24 h
drug exposure was also shown to be Cu-DPPZ-CipA, followed
by Cu-phen-CipA and Cu-DPQ-CipA. Post 24 h drug exposure, a
shift in IC50 values from higher to lower values was observed
for all complexes tested in both cell lines. After 72 h the Cu-
DPPZ-CipA complex was particularly cytotoxic, exhibiting
nanomolar in vitro cytotoxic activity (0.88 ± 0.05 µM) in the
MCF-7 cell line. In addition, IC50 values for Cu-DPQ-CipA and
Cu-phen-CipA decreased by a factor of 2. A similar trend was
observed in the DU145 cell line after 72 h. The most active
complex was again Cu-DPPZ-CipA (1.89 ± 0.33 µM). The other
two complexes, Cu-phen-CipA and Cu-DPQ-CipA, exhibited
comparable cytotoxicities. CipA showed activity greater than
100 µM after 24 h treatment in both cell lines. However, this
Fig. 3 (A) Molecular structure of [Cu(phen)(CipA-H)Cl]·1H2O·1CH3OH
with atomic displacement parameters shown at 50% probability. Only one
conformation of the disordered chain is shown and hydrogen atoms
omitted for clarity. (B) Packing diagram of [Cu(phen)(CipA-H)Cl] (major
moiety) viewed down the c-axis. Hydrogen atoms omitted for clarity.






24 h 72 h 24 h 72 h
Cu-phen-CipA 7.43 ± 0.99 3.05 ± 0.49 5.33 ± 0.70 2.04 ± 0.32
Cu-DPQ-CipA 7.00 ± 0.57 3.13 ± 0.25 5.59 ± 0.28 2.09 ± 0.51
Cu-DPPZ-CipA 2.12 ± 0.41 0.88 ± 0.05 3.27 ± 0.46 1.89 ± 0.33
CipA >100 75.32 ± 3.08 >100 35.95 ± 2.51
Doxorubicin9a 1.44 ± 0.28 0.94 ± 0.19 0.15 ± 0.02 <1.25
[Cu(phen)2]
2+ 6.60 ± 0.60 0.73 ± 0.05 1.73 ± 0.35 0.80 ± 0.19
aData represents mean ± SD of the results of three separate determi-
nations; IC50 (µM) ± SD.
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decreased after 72 h of incubation with IC50 values for the
ligand alone of 75.32 ± 3.08 µM and 35.95 ± 2.51 µM for
MCF-7 and DU145, respectively. A summary of the in vitro cyto-
toxicity data is presented in Table 1.
2.3. DNA binding affinity
Complex binding to double strand DNA (dsDNA) was studied
using competitive ethidium bromide (EtBr) fluorescence dis-
placement on ctDNA, ultrahigh purity using a previously pub-
lished method.34 Binding activity was confirmed using a
second polymer, salmon testes DNA (stDNA), the details of
which are included in ESI.† Quenching analysis of Hoechst
33258 (groove binder) and EtBr (intercalator) were also
employed to identify the binding mode.
A high throughput competitive EtBr displacement assay
was employed in which an optimised mixture of ctDNA
(10 μM) and EtBr (12.6 μM) was incubated for 1 h with added
quencher ([drug]) in a total volume of 100 μL buffer, Fig. 4.
The fluorescent quenching study, in contrast, comprised
ctDNA (50 μM) and EtBr (10 μM) or Hoechst 33258 in HEPES
buffer (80 mM) with added drug, Fig. 5. Measurements were
conducted using excitation and emission filters of 360 and
460 nm for Hoechst 33258 and 530 and 590 nm for EtBr. A
reduction in fluorescence, upon treatment with drug, was
indicative of displacement of EtBr bound to DNA. Actinomycin
D and netropsin were used as reference standards due to their
known intercalative and minor groove binding properties,
respectively. Apparent ctDNA binding constants are reported
in Table 2 (A).
The DNA binding constant (Kapp) for [Cu(phen)2]
2+ was
6.67 × 105 M−1, Table 2 (A), consistent with literature reports.34
Interestingly, replacement of one phen ligand with CipA
enhanced DNA binding by one order of magnitude. The pres-
ence of the phenazine ligands, DPQ and DPPZ, in the Cu-N,
N-CipA complexes, were found to significantly enhance DNA
binding with calculated Kapp values of ca. 1.3 × 10
7 M(bp−1)
and ca. 1.0 × 107 M(bp−1) respectively, similar to the Kapp of
actinomycin D (a known intercalator), Table 2 (A), under these
conditions.3a In fact, these Kapp values are akin to the cationic-
phenazine functionalised Cu-phen complexes reported by
Kellett et al.8 Quenching studies (Fig. 5, Table 2 (B)) suggest
that the Cu-N,N-CipA complexes displace DNA-bound Hoechst
to a higher extent than EtBr, Table 2 (B). Reports in the litera-
ture suggest that Q values >20 µM in EtBr quenching studies
on ctDNA are indicative of ‘classical’ DNA intercalation. In con-
trast, minor groove binders have Q values between 2–15 µM.35
We can deduce from our data that the Cu-N,N-CipA complexes
appear to either intercalate (DPPZ and DPQ) or semi-interca-
late (phen) DNA via the minor groove, Table 2 (B). As expected,
no significant quenching was observed for CipA at concen-
trations greater than 300 µM.
To investigate if the redox state of the copper ion was
important for the EtBr displacement induced by these com-
plexes, assays were repeated but in the presence of 3 equiva-
lents of reductant (Na-L-ascorbate) over a wide range of time
points and over a wide concentration range. The results indi-
cated that only Cu-DPQ-CipA reached 50% reduction in fluo-
rescence within the first 5 min. In contrast, the DPPZ and
phen analogues did not reach 50% displacement over this con-
centration range nor over this time period, Fig. S9 (ESI†).
These results indicate that, upon reduction to copper(I), the
complexes do not significantly affect EtBr displacement
suggesting therefore that the 2+ oxidation state is crucial for
the binding and intercalating properties observed for these
complexes. This change in electrostatic charge from 2+ to 1+
may possibly diminish DNA binding activity and account for
the decrease in fluorescence observed when the experiments
were repeated in the presence of the reducing agent.
2.4. Topoisomerase activity
Human topoisomerases are multifunctional enzymes that
relieve topological constraints in DNA during processes includ-
ing chromatin assembly, recombination and chromosome seg-
Fig. 4 Competitive EtBr displacement assays with ctDNA. Data points
are presented as an average of triplicate measurements ± SD. Data
points for CipA are omitted for clarity.
Fig. 5 Competitive EtBr displacement: Fluorescence quenching of
limited bound EtBr intercalator and Hoechst 33258 displacement assays
with ctDNA. Data points are presented as an average of triplicate
measurements ± SD. Data points for CipA are omitted for clarity.
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regation by making transient single- (topo I) or double-strand
(topo II) DNA breaks.36 DNA topoisomerases (topo) are con-
sidered to be the main target of quinolones. In addition,
quinolones can be considered as topoisomerase poisons as
they have the ability to convert gyrase and topoisomerase IV
(two type II topoisomerases) into cellular toxins.37 A recent
study where serine and acidic residues of topoisomerase were
in close proximity to the quinolone structure, showed that the
distance between the amino acids and the quinolone was too
great to facilitate binding. On the other hand, a structure of a
magnesium–quinolone complex incorporating four molecules
of water which had non-catalytic magnesium(II) bound to the
quinolone over the C3/C4 keto acid, confirmed that the co-
ordinated water molecules could interact with the serine and
acidic residues via hydrogen bonding interactions.38 The pres-
ence of a metal ion–water complex suggests that serine and
acidic residues act as anchor points which enhance the coordi-
nation of the bridge to the enzyme and that the water–metal
ion bridge is the primary interaction between the drug and
bacterial type II enzymes.39 Importantly, serine and acidic resi-
dues needed to affix this water–metal ion bridge are not
present in human type II topoisomerase, leading to the elimin-
ation of this key mechanism, making the toxicity of quino-
lones negligible for humans.39,40
The topoisomerase I mediated DNA relaxation assay was
employed to probe the DNA binding properties of the Cu-N,
N-CipA series. Cu-phen-CipA was found to induce complete
relaxation of negatively supercoiled DNA (−) to the open circu-
lar form (0) at 50 µM with positive supercoiling (+) occurring
thereafter. When the ligated N,N ligand was systematically
extended from 1,10-phenanthroline to DPQ and further
extended to DPPZ, the concentration required to relax scDNA
reduces to 5.0 and 2.5 µM respectively with an increase in DNA
damage observed at higher loading values. All complexes
within this series were identified to intercalate (DPQ and
DPPZ) or semi-intercalate (phen) and unwind negatively super-
coiled plasmid DNA inhibiting topoisomerase I enzymatic
activity with the overall trend: Cu-DPPZ-CipA > Cu-DPQ-CipA >
Cu-phen-CipA. Designer phenazine systems in the Cu-N,
N-CipA model had a significant impact on the inhibition of
the topoisomerase I enzyme as the concentration required to
relax scDNA when compared to Cu-phen-CipA, Fig. 6.
2.5. Chemical nuclease activity
The ability of the complexes to cleave DNA was also assessed,
in the presence and absence of reactive oxygen species (ROS)
scavengers, using electrophoretic mobility shift assays on
supercoiled (FI, bottom band) pUC19 DNA, Fig. 7. The chemi-
cal nuclease activity of the complexes was compared to that of
[Cu(phen)2]
2+ which we have previously reported.9a The pro-
Fig. 6 Topoisomerase I mediated DNA relaxation in the presence of
Cu-N,N-CipA complexes (where N,N = phen, DPQ or DPPZ). Negatively
supercoiled (SC) pUC19 was initially incubated with increasing concen-
trations of each complex (0.1–400 µM) prior to treatment with topo-
isomerase I. The positive (+), relaxed open circular (0) and negative (−)
helical superturns are presented below the gels.
Table 2 (A) Apparent ctDNA binding constants (Kapp) as determined by competitive EtBr competitive quenching, (B) fluorescence quenching (Q)





b (M(bp)−1) Qc Hoechst 33258 (µM) Qd EtBr (µM)
Actinomycin D 4.10 2.92 × 107 26.34 4.78
Netropsin 46.27 2.50 × 106 2.40 20.04
[Cu(phen)2]
2+ 179.21 6.67 × 105 34.96 20.83
CipA >300 (>300) NC >300 (>300) >300 (>300)
Cu-phen-CipA 16.23 (17.35) 7.38 × 106 (6.90 × 106) 14.94 (18.32) 41.56 (41.05)
Cu-DPQ-CipA 8.99 (9.31) 1.33 × 107 (1.29 × 107) 12.19 (12.45) 48.38 (49.93)
Cu-DPPZ-CipA 10.62 (13.26) 1.13 × 107 (9.03 × 106) 14.40 (13.02) 51.49 (48.67)
a C50 is the concentration required to reduce fluorescence by 50%.
b Kapp = Ke × 12.6/C50 where Ke = 9.5 × 10
6 M(bp)−1; values in brackets represent
stDNA data. NC = not calculated. c Q = displacement of 50% initial fluorescence from DNA-bound dye. d Q = concentration required to effect 50%
removal of the initial fluorescence of bound dye.
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cedure employed was adapted from a previously reported
method.41 Briefly, in these experiments, 400 ng of pUC19 DNA
was incubated for 30 min with drug concentrations ranging
from 0.5–2.5 µM for Cu-phen-CipA and Cu-DPQ-CipA and
2.5–20 µM for Cu-DPPZ-CipA, in the presence or absence of
ROS scavengers/stabilisers, before being quenched and exam-
ined using agarose gel electrophoresis. The concentrations of
the test complexes were optimised in which a degradation
profile could be visualised and representative DNA bands of
single strand damage (open circular, FII, below top band) and
double strand damage (linear, FIII, top band) could be identi-
fied, Fig. 7. The scavengers employed were: KI (10 mM) as a
H2O2 scavenger, NaN3 (10 mM) as
1O2 scavenger, DMSO (10%)
as •OH scavenger and tiron (4,5-dihydroxy-1,3-benzenedisulfo-
nic acid disodium salt or TH2) as O2
•− scavenger (10 mM).
We previously reported that the nuclease activity of
[Cu(phen)2]
2+, in the presence of TH2, was found to be signifi-
cantly hindered with cleavage of SC FI pUC19 DNA to FII and
FIII at 1.0 and 2.5 µM. The •OH scavenger, DMSO, was found to
have a similar effect on cleavage activity at these concentrations
while incubation with KI and NaN3 had only marginal effects. It
was concluded from this study that the predominant ROS
responsible for the observed DNA cleavage were O2
•− and •OH.9a
All three complexes were found to likewise exhibit excellent
nuclease activity, Fig. 7. The Cu-phen-CipA and Cu-DPPZ-CipA
complexes possessed lower nuclease activity if compared to
[Cu(phen)2]
2+, where complete degradation of FI to FII and
FIII was observed at 2.5 µM. Significantly, Cu-DPQ-CipA
showed complete degradation of FI to FII and FIII at 0.75 µM,
making it the most efficient nuclease activator in the series. In
the case of Cu-DPPZ-CipA, the main ROS involved in DNA
damage were both O2
•− and •OH where TH2 and DMSO signifi-
cantly inhibited the cleavage efficiency of FI to FII and FIII at
2.5 µM. In addition, DMSO and TH2 were also the scavengers
that exhibited an inhibition of chemical nuclease activity of
Cu-DPQ-CipA possibly indicating that •OH and O2
•− species
were involved in inducing DNA damage for this complex also.
However, DMSO proved to be the best scavenger of the series,
suggesting that O2
•− is most likely the predominant ROS that
mediates DNA damage. Furthermore, the Cu-phen-CipA was
the only complex in the series that showed all four ROS being
important for its nuclease activity – complete degradation of
FI to FII and FIII observed at 1.25 µM could be inhibited with
all four ROS scavengers. Of note is the fact that the presence of
the CipA in these complexes did not adversely impact on their
ability to induce significant nuclease activity.
2.6. In vitro bactericidal and fungicidal activity
The bactericidal and fungicidal activity of the ligands and
complexes toward a range of Gram positive (Staphylococcus
aureus (SA); methicillin resistant Staphylococcus aureus (MRSA);
Enterococcus sp. (EF) and Staphylococcus epidermidis (SE)) and
Gram negative bacteria (Escherichia coli (EC); Klebsiella pneu-
moniae (KP); Klebsiella pneumoniae ESBL positive (KP-E) and
Pseudomonas aeruginosa (PA)) were examined along with their
effect on non-filamentous fungi (Candida albicans ATCC 44859
(CA1); Candida albicans ATCC 90028 (CA2); Candida parapsilo-
sis ATCC 22019 (CP); Candida krusei ATCC 6258 (CK1); clinical
yeast isolates (Candida krusei E28 (CK2); Candida tropicalis 156
(CT); Candida glabrata 20/I (CG); Candida lusitaniae 2446/I
(CL); Trichosporon asahii 1188 (TA)), and filamentous fungi
(Aspergillus fumigatus 231 (AF); Absidia corymbifera 272 (AC)
and Trichophyton mentagrophytes 445 (TM)), Tables 3 and 4.
Briefly, the activity of the phenazine ligands, the Cu-N,N-CipA
complexes and Cip ligand were tested at 24 and 48 h time
points across the above mentioned panel of bacteria and fungi.
The exception was Trichophyton mentagrophytes 445 (TM) which
was tested at 72 and 120 h. Due to solubility issues, the
minimum inhibitory concentrations that induce 95% bacterial
growth inhibition (MIC95) of CipA could not be evaluated as the
desired concentration needed for these experiments could not
be achieved. The anti-microbial activity of Cip, however, was as
expected with MIC95 values ranging from 1.95–3.9 µM against
SA, 0.98–1.95 µM against EC and KP and 3.9–7.81 µM against
EF at 24 h and 48 h, respectively. No significant activity was
observed against MRSA, SE and KP-E with MIC95 values of
125 µM. The activity of phen, DPQ and DPPZ varied with MIC95
values ranging from 3.90–2000 µM. The DPPZ ligand exhibited
greatest potency with MIC95 values ranging from 3.90, 7.81 and
15.62 µM against SE, SA and MRSA strains respectively.
The most active complexes in the series were Cu-phen-CipA
and Cu-DPPZ-CipA with MIC95 ranging from 7.81–31.25 µM
across the Gram positive strains. The complexes exhibited
moderate to poor activity against the Gram negative strains
(MIC95 values ranging from 31.25 to >125 µM), suggesting that
these Cu-N,N-CipA complexes selectively target Gram positive
bacteria. Interestingly, although all the Cu-N,N-CipA com-
plexes were more potent against MRSA and SE relative to Cip,
the Cu-DPPZ-CipA complex was most potent, with a MIC95 of
Fig. 7 DNA cleavage reactions with complexes from the series in the
presence or absence of ROS specific scavengers: 400 ng of SC pUC19
was incubated for 30 min at 310 K with concentrations of 0.5 (lane 1),
0.75 (lane 2), 1.25 (lane 3) and 2.5 µM (lane 4) Cu-phen-CipA/Cu-
DPQ-CipA; 2.5 (lane 1), 5 (lane 2), 10 (lane 3) and 20 µM (lane) Cu-
DPPZ-CipA; in the presence of 25 mM NaCl, 0.5 mM Na-L-ascorbate
and 80 mM HEPES.
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Table 3 In vitro bactericidal activity data (MIC95) towards Gram-positive and Gram-negative bacterial strains
MIC95 (µM)
Gram positive bacteriaa Gram negative bacteriab
SA MRSA SE EF EC KP KP-E PA
Compound 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
phen 125 ND 500 ND 1000 ND 62.5 ND 2000 ND 1000 ND 1000 ND 2000 ND
DPQ 62.5 62.5 62.5 125 125 125 62.5 62.5 250 500 500 500 5000 500 500 500
DPPZ 7.81 7.81 7.81 15.62 3.90 3.90 125 250 500 500 500 500 500 500 500 500
[Cu(phen)2]
2+ 31.25 31.25 15.62 15.62 62.5 62.5 15.62 15.62 62.5 62.5 62.5 62.5 62.5 62.5 1000 1000
Cu-phen-CipA 15.62 15.62 31.25 31.25 31.25 31.25 62.5 62.5 62.5 62.5 >125 >125 >125 >125 >125 >125
Cu-DPQ-CipA 7.81 31.25 31.25 31.25 62.5 125 62.5 125 >125 >125 >125 >125 >125 >125 >125 >125
Cu-DPPZ-CipA 7.81 15.62 15.62 15.62 15.62 15.62 31.25 62.5 >125 >125 >125 >125 >125 >125 >125 >125
Cip 1.95 3.9 125 125 125 125 3.9 7.81 0.98 1.95 0.98 1.95 125 125 31.25 31.25
a Staphylococcus aureus (SA), methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis (SE) and Enterococcus sp. (EF). b Escherichia coli (EC), Klebsiella pneumoniae (KP),
Klebsiella pneumonia ESBL positive (KP-E) and Pseudomonas aeruginosa (PA). ND = not determined.
Table 4 In vitro fungicidal activity data towards non-filamentous fungi (MIC80) and towards filamentous fungi (MIC50). MIC50 of TM strain was determined at 72 and 120 h, whereas MIC50 of all
other strains were determined at 24 and 48 h
Non-filamentous fungi (ATCC strains)a – MIC80 (µM) Non-filamentous fungi (clinical yeast isolates)
b – MIC80 (µM) Filamentous fungi
c – MIC50 (µM)
CA1 CA2 CP CK1 CK2 CT CG CL TA AF AC TM
Compound 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 72 h 120 h
phen 7.81 ND 7.81 ND ND ND 7.81 ND 7.81 ND 31.25 ND 7.81 ND 15.62 ND 7.81 ND 15.62 15.62 15.62 15.62 7.81 7.81
DPQ 31.25 31.25 31.25 31.25 31.25 31.25 62.5 62.5 62.5 62.5 125 125 31.25 125 31.25 31.25 31.25 31.25 62.5 62.5 31.25 31.25 31.25 31.25
DPPZ 62.5 500 62.5 500 500 500 500 500 500 500 500 500 62.5 500 500 500 7.81 7.81 500 31.25 500 500 500 500
[Cu(phen)2]
2+ 15.62 15.62 15.62 15.62 15.62 15.62 7.81 7.81 15.62 15.62 31.25 31.25 15.62 15.62 7.81 7.81 15.62 15.62 31.25 31.25 31.25 31.25 15.62 15.62
Cu-phen-CipA 125 125 125 125 125 125 62.5 62.5 62.5 62.5 125 125 125 125 >125 >125 125 125 >125 >125 >125 >125 >125 >125
Cu-DPQ-CipA 125 125 125 125 125 125 31.25 31.25 31.25 31.25 >125 >125 >125 >125 62.5 62.5 >125 >125 >125 >125 >125 >125 >125 >125
Cu-DPPZ-CipA >125 >125 >125 >125 >125 >125 15.62 15.62 15.62 15.62 62.5 62.5 62.5 62.5 31.25 31.25 >125 >125 >125 >125 >125 >125 >125 >125
Cip >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125
a Candida ablicans ATCC 44859 (CA1), Candida ablicans ATCC 90028 (CA2), Candida parapsilosis ATCC 22019 (CP) and Candida krusei ATCC 6258 (CK1). b Candida krusei E28 (CK2), Candida
tropicalis 156 (CT), Candida glabrata 20/I (CG), Candida lusitaniae 2446/I (CL) and Trichosporon asahii 1188 (TA). c Aspergillus fumigatus 231 (AF), Absidia corymbifera 272 (AC) and Trichophyton
































































































15.62 µM in contrast to Cip which had an MIC95 of 125 µM
against the same strain. Methicillin-resistant S. aureus or
MRSA is known to be a major causative agent of community-
acquired infections.42 Antibiotic resistance in S. aureus has
also become a major challenge. According to a report recently
released by the World Health Organization (WHO), most anti-
biotic agents under development are modifications of existing
antibiotics.43 They highlight the need to develop innovative
approaches to cater for the anticipated further evolution of re-
sistance. Combining antibiotics with metal ions such as
copper(II) may represent an innovative approach in this field
and already some groups are advancing this line of research.44
From our findings, the Cu-N,N-CipA derivatives may serve as
potential new leads. Their mode of bactericidal activity thus
warrants further investigation. A summary of the in vitro bac-
tericidal activity of the Cu-N,N-CipA derivatives is presented in
Table 3 and Fig. 8.
While Cip demonstrated potent bactericidal activity in a
number of Gram positive and Gram negative bacterial strains,
Table 3, it exhibited no fungicidal activity in all fungal strains
tested, with determined MIC50 and MIC80 values >125 µM in
all cases. In contrast to the anti-bacterial properties, the
in vitro anti-fungal activity of the metal-free phen ligand sur-
passed that of all of the complexes tested, with consistent
MIC50 and MIC80 values ranging from 7.81–15.62 µM in all the
fungal strains tested. This observation is in agreement with pre-
viously published results,3c most likely due to the ability of this
ligand to bind trace metal ions (e.g. zinc(II)) which are essential
for fungal survival. The [Cu(phen)2]
2+ complex exhibited broad
spectrum anti-fungal activity across the panel line tested. The
Cu-N,N-CipA complexes, in contrast, showed little anti-fungal
activity towards the panel tested, with the exception of Cu-
DPPZ-CipA which had an MIC80 of 15.62 µM toward the CK1
and CK2 strains and an MIC80 of 31.25 µM toward the CL
strain. A summary of the in vitro fungicidal activity of the Cu-N,
N-CipA derivatives is presented in Table 4 and Fig. S10 (ESI†).
2.7. In vivo toxicity using Galleria mellonella
The immune system of insects bears remarkable functional
and structural similarities to that of the innate immune system
of mammals.45 As such, insects may be employed as models for
studying the virulence of human pathogens46 and for assessing
the in vivo efficacy of novel anti-microbial drugs.47 Larvae of the
greater wax moth, G. mellonella, have been successfully
employed for this purpose. Numerous studies have indicated a
strong correlation between results obtained using this insect
model and those obtained using mammals.46,48 Larvae of
G. mellonella, for example, have been successfully utilised for
assessing the toxicity of food preservatives49 and, of particular
note, novel silver based anti-cancer drugs.50
The effect of the Cu-phen-CipA, Cu-DPQ-CipA and Cu-
DPPZ-CipA complexes and the CipA ligand on the viability of
G. mellonella larvae was therefore assessed, Fig. 9. The larvae
were administered test solutions by injection directly into the
haemocoel through the last pro-leg across a concentration
range from 50–1000 µg mL−1. Larvae survival was monitored
after 24, 48 and 72 h of test compound exposure and death
noted by their lack of movement in response to a stimulus and
cuticle discoloration.
The CipA and all complexes tested were well tolerated by
the larvae, Fig. 9. Of the complex series, the Cu-DPQ-CipA was
the least toxic with no kill observed after 72 h exposure across
the concentration range. The Cu-phen-CipA complex was
found to be the most toxic at the highest concentration tested
(1000 µg mL−1) with ca. 30% kill after 24 h of exposure. The
Cu-DPPZ-CipA complex was shown to be less toxic at the same
time point and also at the highest concentration with ca. 23%
kill. After a further 48 h of exposure (72 h in total), the Cu-
phen-CipA complex induced further death (ca. 36%) while Cu-
DPPZ-CipA remained unchanged. At the same time point
(72 h) of exposure at the lowest tested concentration, 7–10% of
larvae were killed in the case of Cu-DPQ-CipA, Cu-DPPZ-CipA
and CipA. However, this can occur often due to an infection
Fig. 8 Bactericidal activity of the N,N-ligands, Cip and Cu-N,N-CipA
derivatives across a panel of Gram positive ((Staphylococcus aureus (SA);
methicillin resistant Staphylococcus aureus (MRSA); Enterococcus sp.
(EF) and Staphylococcus epidermidis (SE)) and Gram negative bacteria
(Escherichia coli (EC); Klebsiella pneumoniae (KP); Klebsiella pneumo-
niae ESBL positive (KP-E) and Pseudomonas aeruginosa (PA)).
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and may not necessarily correlate with these test agents. These
results provide preliminary evidence that the Cu-N,N-CipA
complexes are well tolerated by the larvae which bodes well for
their general in vivo toxicity profile.
3. Conclusions
We have successfully employed a one-pot synthetic protocol to
generate a library of copper(II) complexes of general formula
[Cu(N,N)(CipA)Cl] where N,N represents a phenanthrene
ligand and CipA, a derivative of the clinically used fluoroqui-
nolone antibiotic ciprofloxacin. These complexes were ration-
ally designed so as to incorporate a Cu-N,N-framework with
DNA binding and DNA oxidant properties and an antibiotic
derivative with known anti-proliferative and anti-microbial
activities. Based on X-ray structural analysis, the [Cu(Phen)
(CipA)Cl] complex exists in a slightly distorted square pyrami-
dal geometry with the copper(II) ion coordinated by two CipA O
atoms and two phen N atoms in the equatorial plane, and by a
Cl ion in the axial position. Of the complex series, the quinoxa-
line and phenazine complexes, Cu-DPQ-CipA and Cu-
DPPZ-CipA, exhibited excellent DNA binding affinities with
Kapp values in the 10
7 M(bp)−1 range. All complexes appeared
to intercalate DNA via minor groove interactions and to
mediate DNA damage by generating ROS with superoxide and
hydroxyl free radicals playing crucial roles in DNA strand
scission. The complexes were highly cytotoxic against a human
breast adenocarcinoma (MCF-7) and a human prostate carci-
noma cell line (DU145), the latter being p53 null, with low
micromolar cytotoxicities observed after 24 h of treatment in
contrast to CipA (IC50 > 100 µM). The Cu-DPPZ-CipA complex,
in particular, was found to be highly cytotoxic (nanomolar
range) against the breast carcinoma cells after 72 h. Given that
topoisomerases are one of the main targets of fluoroquinolone
antibiotics, the complexes were assessed for their topoisome-
rase inhibitory activity. Of the series, the Cu-DPPZ-CipA
complex exhibited the greatest inhibitory activity.
Furthermore, the complexes appear to selectively target Gram
positive bacteria over Gram negative bacteria with Cu-
DPPZ-CipA having an order of magnitude greater potency
against Methicillin-resistant S. aureus (MRSA) as compared to
the free CipA ligand. In addition, the CipA ligand and all the
complexes tested were well tolerated by a widely adopted
in vivo insect model which bodes well for their future develop-
ment as drugs. Taking all these facts into consideration, these
complexes, but particularly Cu-DPPZ-CipA as the lead drug
candidate, have significant potential to act as novel prophylac-
tic metallo-antibiotics for the treatment of cancer patients at
high risk of infection and thus warrant further investigation.
Given that antibiotic resistance in S. aureus has become a
major challenge, there is an urgent need to identify new
approaches to cater for the anticipated further evolution of re-
sistance. These complexes may thus also offer promise as
metallo-antibiotics in their own right.
4. Experimental section
4.1. Materials and methods
EtBr, netropsin, actinomycin D, DMF and Hoechst 33258 were
purchased from Sigma-Aldrich (Arklow, Ireland) and used as
received. pUC19 vector (N3041) was purchased from New
England Bio-Labs (NEB), UltraPure Calf Thymus DNA from
Invitrogen (ctDNA, ε260 = 12 824 M(bp)
−1 cm−1) and salmon
testes DNA from Sigma Aldrich Ireland (stDNA, ε260 = 13 423
M(bp)−1 cm−1). NaCl and HEPES were obtained from Ambion
while 1 M HEPES buffer (pH 7.2) was purchased from Fisher
Scientific. 1,10-Phenanthroline-5,6-dione (phendione), DPQ
and DPPZ were prepared as previously reported in literature.8
1H and 13C spectra were recorded using a Bruker DPX 400
spectrometer (room temperature; 400 MHz and 101 MHz,
respectively). Coupling constants ( J) are quoted in Hz. The
splitting of the proton resonances is labelled as s = singlet, d =
doublet, t = triplet, sept = septet, m = multiplet. Chemical
shifts (δ) are quoted in parts per million (ppm) using residual
protons in the indicated solvents as internal standards. NMR
data processing was carried out using MestReNova, version
6.0.2-5475. Infrared spectra were recorded on a Bruker Tensor
27 spectrometer with KBr as a standard. IR spectra were ana-
lysed using OPUS, version 5.0, with peak positions (ν) in cm−1.
Mass spectrometry was carried out on an Advion Expression
Compact Mass Spectrometer: 10 µL of the samples were
Fig. 9 % Survival of G. mellonella exposed to different agents for 24 h,
48 h and 72 h. Data represent mean ± SEM of the results of three separ-
ate determinations.
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injected in 300 µL of methanol : water : formic acid (90 : 9 : 1
v/v). Microanalysis was carried out at the Department of
Chemistry, University College Dublin.
4.2. Syntheses
The ligands 1,10-phenanthroline-5,6-dione (phendione), dipyr-
ido[3,2-f:2′,3′-h]quinoxaline (DPQ), dipyrido[3,2-f:2′,3′-h]qui-
noxaline (DPQ) and dipyrido[3,2-a:2′,3′-c]phenazine (DPPZ)
were prepared according to previously prublished methods.8
4.2.1. Synthesis of [Cu(1,10-phen)(CipA-H)Cl] (Cu-phen-
CipA). CuCl2·2H2O (70.2 mg, 0.412 mmol, 1 eq.) was dissolved
in water (6 mL) and a hot solution of phen (74.2 mg,
0.412 mmol, 1 eq.) in EtOH (10 mL) added. To this was added
previously dissolved CipA (200 mg, 0.412 mmol, 1 eq.) in
MeOH (15 mL) with NaOH (16 mg, 0.412 mmol, 1 eq.) in water
(2.5 mL). The pH was adjusted to ca. 8 with 0.2 M NaOH. The
round bottom flask was sealed with parafilm and left to stir at
room temperature overnight. The flask was left open at room
temperature and after two days turquoise to dark green crystals
were deposited. Crystals were isolated by filtration and dried in
a desiccator to yield dark green crystals (0.316 mmol, 77%).
ESI-MS (positive mode; MeOH) m/z 762.23 [M], 727.02
[M − Cl]+. IR selected bands (cm−1, KBr): 2914, 2851, 1620,
1588, 1515, 1478, 1303, 1250, 1224, 1025, 945, 858, 726 cm−1.
Anal. Calcd for C39H43ClCuFN5O4·3H2O: C, 57.28; H, 6.04; N,
8.56; Cu, 7.77. Found: C, 57.14; H, 5.70; N, 8.30; Cu, 7.39.
4.2.2. Synthesis of [Cu(DPQ)(CipA-H)Cl] (Cu-DPQ-CipA).
CuCl2·2H2O (35.1 mg, 0.206 mmol, 1 eq.) was dissolved in
water (4 mL) and a hot solution of DPQ (47.8 mg, 0.206 mmol,
1 eq.) in EtOH (8 mL) added. In parallel, CipA (100 mg,
0.206 mmol, 1 eq.) was dissolved in MeOH (6 mL) followed by
the addition of NaOH (8 mg, 0.206 mmol, 1 eq.) in H2O (3 mL)
and added to the Cu salt solution (∼318 K). The pH was
adjusted to ca. 8 with 0.2 M aq. NaOH. The round bottom
flask was sealed with parafilm and left to stir at room tempera-
ture overnight. The following day, a green solid was isolated by
filtration, washed with cold H2O, cold MeOH and dried in a
desiccator to yield a light green solid (0.098 mmol, 48%).
ESI-MS (positive mode; MeOH) m/z 814.23 [M], 779.10
[M − Cl]+. IR selected bands (cm−1, KBr): 2920, 2853, 1613,
1579, 1523, 1477, 1383, 1301, 1247, 1083, 1023, 951, 887,
730 cm−1. Anal. Calcd for C41H43CuClFN7O4·2H2O·1.5C2H5OH:
C, 57.38; H, 6.13; N, 10.65; Cl, 3.85. Found: 57.22; H, 5.69; N,
10.28; Cl, 3.82.
4.2.3. Synthesis of [Cu(DPPZ)(CipA-H)Cl] (Cu-DPPZ-CipA).
CipA (100 mg, 0.206 mmol, 1 eq.) was dissolved in hot MeOH
(7 mL) and had an aqueous solution (2 mL) of NaOH (8 mg,
0.206 mmol, 1 eq.) added. After 5 min of stirring, CuCl2·2H2O
(35.1 mg, 0.206 mmol, 1 eq.) dissolved in water (3 mL) and
DPPZ (58.14 mg, 0.206 mmol, 1 eq.) dissolved in hot MeOH
(6 mL) were added slowly and simultaneously to the CipA solu-
tion (∼318 K). The pH was adjusted to ca. 8 with 0.2 M NaOH.
The round bottom flask was sealed with parafilm and left to
stir at room temperature overnight. The following day, a green
solid was isolated by filtration and washed with cold H2O, cold
MeOH and dried in a desiccator resulting in a bright green
solid (0.121 mmol, 59%). ESI-MS (positive mode; MeOH) m/z
864.25 [M], 829.05 [M − Cl]+. IR selected bands (cm−1, KBr):
2925, 2853, 1619, 1586, 1519, 1471, 1356, 1298, 1258, 1074,
1023, 949, 883, 732 cm−1. Anal. Calcd for
C45H45ClCuFN7O4·3H2O: C, 58.66; H, 5.18; N, 10.32; Cl,
3.32; Cu, 6.91. Found: C, 58.75; H, 5.59; N, 10.66; Cl, 3.85; Cu,
6.91.
4.3. Structure analysis of Cu-phen-CipA (8)
The X-ray structural analysis of a crystal of [Cu(phen)(CipA-H)
Cl]·1H2O·1CH3OH was performed on a Bruker D8 Quest Eco at
100(2) K with an Oxford Cryosystems cryostat, with samples
mounted on a MiTeGen microloop using Mo Kα radiation (λ =
0.71073 Å). Bruker APEX (Bruker (2016). APEX3 v2016.9-0,
Bruker AXS Inc., Madison, WI, USA) software was used to
collect and reduce data and determine the space group.
Absorption corrections were applied using SADABS (Bruker
(2016/2). SADABS, Bruker AXS Inc., Madison, Wisconsin, USA).
The structure was solved with the XT structure solution
program51 using Intrinsic Phasing and refined with the XL
refinement package52 using Least Squares minimisation in
Olex2.53 All non-hydrogen atoms were refined anisotropically.
Hydrogen atoms were assigned to calculated positions using a
riding model with appropriately fixed isotropic thermal
parameters.
The aliphatic chain was modelled in two conformations
(occupancy 52 : 48%) using restraints and constraints (SADI,
EADP). The structure was refined as an inversion twin in the
chiral space group P212121 with a BASF of 0.100(18).
See Table 5 for crystal data and structure refinement para-
meters. Crystallographic data, CCDC 1586315.†
















r (Mg cm−3) 1.418
m (mm−1) 702





a [I > 2σ(I)] 0.0442
wR2
b [I > 2σ(I)] 0.0862
CCDC 1586315
a R1 = ∑||Fo| − |Fc||/∑|Fo|. bwR2 = [∑w(Fo2 − Fc2)2/∑w(Fo2)2]1/2.
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Cells were cultured in a standard 75 cm3 flask (Corning®,
Austria) containing Roswell Park Memorial Institute medium
(RPMI-1640; Sigma-Aldrich, Ireland) supplemented with 10%
fetal bovine serum (Gibco®, Ireland) at 310 K in a humidified
atmosphere at 5% CO2. Cells were cultured in a mycoplasma-
free facility and were routinely tested for mycoplasma contami-
nation with MycoAlert™ Mycoplasma Detection Kit (Lonza).
Every 3–4 days cells reached 70–80% confluency after which
they were harvested with trypsin-EDTA (ATCC, LGC, United
Kingdom) and re-suspended in media. The in vitro inhibition
of human cancer cell line growth by means of the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Sigma-Aldrich, Belgium) colourimetric anti-proliferation assay
was utilised.
Briefly, prior to addition of tested agents, MCF-7 and
DU145 cells were seeded overnight in 96-well tissue culture
plates (Costar) at an initial density of 4 × 105 and 2 × 105 cells
per mL for 24 h and 72 h incubation points, respectively.
DMSO stock suspensions of complexes were prepared at
∼40 mM. Prepared stocks were further on diluted in sup-
plemented medium to give the following final concentrations
in 200 µL wells: 100, 50, 10, 5, 1, 0.5 and 0.1 µM. A DMSO
control over the same concentration range was included each
time. Cells grown in 96-well plates often clump towards the
outer edges of the wells. This tendency, commonly called ‘edge
effect’ was minimised by filling the inter-well spaces of a
96-well tissue culture plate with 50 µL of sterile PBS. Cells were
incubated for 24 and 72 h at 310 K in a humidified atmo-
sphere with 5% CO2. After the desired incubation period,
spent media was removed and cells were washed with PBS.
100 µL fresh media and 10 µL of 5 mg mL−1 MTT solution
giving final concentration of 0.5 mg mL−1 were added followed
by incubation for 3 hours at 310 K (protected from light with
aluminium foil). Afterwards, all media was carefully removed,
and the resulting violet formazan crystals were dissolved by
addition of 150 µL of MTT solubilisation solution (0.1%
Tergitol-type NP-40, 4 mM HCl and anhydrous isopropanol)
for 20 min while the 96-well tissue plate was shaking. After
complete dissolution of the formazan product, the absorbance
was measured at 570 nm using 690 nm as the reference wave-
length (background cells and proteins). IC50 values, as the con-
centration which caused 50% of cell death, were determined
as duplicates of triplicate in three independent sets of experi-
ments and their standard deviations were calculated. Cells
exposed to [Cu(phen)2]
2+ as well as untreated cells were used
as positive and negative controls respectively.
4.5. In vivo toxicity activity using Galleria mellonella
G. mellonella larvae (Lepidoptera: Pyralidae, the Greater Wax
Moth), in the sixth developmental stage, were used to deter-
mine the in vivo toxicity of CipA and the Cu-N,N-CipA com-
plexes using a previously published methodology.54 Larvae
were obtained from the Mealworm Company in Sheffield,
England and stored in wood shavings in the dark at 288 K to
prevent pupation. The weight of each larvae was between
0.25–0.3 g and only healthy larvae that showed no evidence of
localised melanisation or infection with no cuticle discolour-
ation were included in the study. The experiment was carried
out on three different occasions in duplicate using a group
size of 10 larvae per 9 cm sterile Petri-dish. Fresh solutions of
the test compounds were prepared immediately prior to
testing under sterile conditions. Each compound was dissolved
in 10% DMSO/PBS to give a stock solution of concentration
100 µM. All agents were tested across the concentration range
100, 10, 1 and 0.1 µM. Test solutions (20 µL) were directly
injected into the haemcoel of the larvae through the last pro-
leg – the proleg can be opened by applying gentle pressure to
the sides of the larvae. This prevents damage to the larvae as
this opening will re-seal following removal of the syringe
needle without leaving a scar. Larvae were placed in sterile
petri-dishes and incubated at 303 K for 72 h. Wood shavings
were provided as a source of food. Larvae injected with sterile
10% DMSO/PBS and untreated larvae were used as controls.
The survival of the larvae was monitored every 24 h.
Determination of death was confirmed by the lack of move-
ment in response to stimulus – a blunt-ended needle was used
to probe the larvae. If the larvae did not respond to this stimu-
lus, then they were considered to be non-viable or dead.
4.6. DNA binding affinity and intercalative studies
4.6.1. Competitive EtBr displacement. Competitive EtBr
displacement assays were conducted using a method pre-
viously reported by Kellett et al.3c,34 Briefly, a working solution
of 20 µM ctDNA or stDNA; 25.2 µM EtBr; 40 mM NaCl in
HEPES buffer (80 mM, pH 7.2) were prepared. Stock solutions
of the Cu-N,N-CipA complexes and groove binding drugs were
prepared in DMSO at ∼5 mM and further diluted with 80 mM
HEPES. 50 µL of a DNA-EtBr working solution were placed into
each well of a 96-well micro plate, with the exception of blanks
which contained 100 µL of HEPES buffer. Serial aliquots of the
metal complexes and groove binding drugs were added to the
working solution and the final volume was adjusted to 100 µL
in each well such that the final concentrations of ctDNA or
stDNA and EtBr were 10 and 12.6 µM, respectively. The plate
was incubated at room temperature for 1 hour, protected from
light. Microplates were analysed using a Bio-Tek synergy HT
multi-mode micro plate reader with excitation and emission
wavelengths set to 530/590 nm respectively. Each drug concen-
tration was measured in triplicate and the apparent binding
constants were calculated using the equation Kapp = Ke × 12.6/
C50, where Ke = 9.5 × 10
6 M(bp)−1.
4.6.2. Fluorescence quenching. This experiment was
carried out as previously described by Kellett et al.3c,8,34 A
working solution of 50 µM ctDNA or stDNA along with either
10 µM EtBr or Hoechst 33258 in HEPES buffer (80 mM, pH =
7.2) and NaCl (40 mM) was prepared. Stock solutions of the
Cu-N,N-CipA complexes and CipA free ligand and groove
binding drugs were prepared at ∼5 mM in DMSO and diluted
further with 80 mM HEPES. 50 µL of DNA-EtBr or
DNA-Hoechst working solutions were placed in each well of a
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96-well microplate with the exception of the blanks which con-
tained 100 µL HEPES buffer and 5 µM of either Hoechst or
EtBr. Serial aliquots of the agents were added to the working
solutions and the volume was adjusted to 100 µL in each well
such that the final concentration of ctDNA or stDNA and EtBr/
Hoechst were 25 µM and 5 µM, respectively. Each drug concen-
tration was measured in triplicate. The plate was allowed to
incubate at room temperature for 5 min before being analysed
using a Bio-Tek synergy HT multi-mode micro plate reader with
excitation and emission wavelengths being set to 530/590 nm
for EtBr detection or 360/460 nm for Hoechst 33258 detection.
Concentrations of tested compounds applied were chosen
based on the fact that their fluorescence was in the range from
30–40% of the initial control at their highest reading. Q values
can be obtained from a plot of fluorescence versus drug concen-
tration and represents the concentration required to affect 50%
removal of the initial fluorescence of bound dye.34
4.6.3. Chemical nuclease activity. The presence or absence
of ROS specific scavengers were used to determine the effect
on the DNA cleavage abilities of each copper complex. Briefly,
in a final volume of 20 µL, 80 mM HEPES (pH = 7.2), 25 mM
NaCl, 1 mM Na-L-ascorbate, and 400 ng of pUC19 DNA were
treated with drug concentrations of 0.5, 0.75, 1.25 and 2.5 µM
(Cu-phen-CipA and Cu-DPQ-CipA) and 2.5, 5.0, 10, 20 µM (Cu-
DPPZ-CipA) in the presence or absence of ROS scavengers/stabil-
isers: KI (10 mM, H2O2 scavenger), NaN3 (10 mM,
1O2 scaven-
ger), DMSO (10%, •OH scavenger) and tiron (TH2, 10 mM, O2
•−
scavenger). Reactions were incubated for 30 minutes at 310 K
and quenched with 6× loading dye (Fermentas) containing
10 mM Tris-HCl, 0.03% bromophenol blue, 0.03% xylene
cyanole FF, 60% glycerol and 60 mM EDTA. Samples were then
loaded onto an agarose gel (1.2%) containing 3 µL of EtBr.
Electrophoresis was completed within two cycles; 50 V for
30 min and 70 V for 1 h in 1× TAE buffer, respectively.
4.6.4. Topoisomerase activity. The topoisomerase I relax-
ation was carried out according to methods previous described
with changes made to the procedure.55 To a final volume of
20 µL; in 80 mM HEPES, 2 µL CutSmart buffer (NEB, B7204),
1 µL 100× BSA (20 mg mL−1) (NEB, B9000) and 400 ng pUC19
DNA were exposed to varying concentrations of each complex
(0.01, 0.025, 0.05, 0.1, 0.5, 0.75, 1, 2.5, 7.5, 10, 20, 50, 100, 200,
400 µM) from HEPES stock for 30 min at room temperature.
Subsequently 1 unit of E. coli topoisomerase I (NEB, M0301)
was added and incubated for 15 min at 310 K. Reactions were
quenched with SDS 0.25% and 250 µg mL−1 proteinase K
(both from Sigma Aldrich, Ireland). Proteins were denatured
with 30 min incubation at 323 K. 6× loading dye (Fermentas)
was added to samples and loaded onto 1.2% agarose gel and
subjected to gel electrophoresis at 40 V for 4 h and 50 V for
3.5 h in 1× TBE buffer at room temperature. The gel was post
stained with 25 µM EtBr bath for 10 min and soaked for 24 h
in deionised water.
4.7. In vitro anti-bacterial activity
In vitro anti-bacterial activity of test compounds were evaluated
on a panel of three ATCC strains (Staphylococcus aureus (SA)
ATCC 6538, Escherichia coli (EC) ATCC 8739, Pseudomonas aeru-
ginosa (PA) ATCC 9027) and five clinical isolates (methicillin
resistant Staphylococcus aureus (MRSA) HK5996/08,
Staphylococcus epidermidis (SE) HK6966/08, Enterococcus sp.
(EF) HK14365/08, Klebsiella pneumonia (KP) HK11750/08,
Klebsiella pneumoniae ESBL (KPE) HK14368/08) from the col-
lection of bacterial strains deposited at the Department of
Biological and Medical Sciences, Faculty of Pharmacy, Charles
University, Hradec Králové, Czech Republic. The above-men-
tioned ATCC strains also served as the quality control strains.
All the isolates were maintained on Mueller-Hinton (MH) agar
prior to being tested.
Minimum inhibitory concentrations (MICs) were deter-
mined by a modified Clinical and Laboratory Standards
Institute (CLSI) standard of microdilution format of the M07-
A7 document.44 DMSO (100%) served as a diluent for all com-
pounds; the final concentration did not exceed 2%. MH agar
(HiMedia, Cadersky-Envitek, Czech Republic) buffered to pH
7.4 (±0.2) was used as the test medium. The wells of the micro-
dilution tray contained 200 µL of the MH medium with 2-fold
serial dilutions of the compounds (1000–0.244 µmol L−1) and
10 μL of inoculum suspension. Inoculum in MH medium was
prepared to give a final concentration of 0.5 McFarland scale
(1.5 × 108 CFU mL−1). The trays were incubated at 310 K, and
MICs were read visually after 24 and 48 h. The MICs were
defined as 95% inhibition of the control growth. MICs were
determined twice and in duplicate. The deviations from the
usually obtained values were no higher than the nearest con-
centration value up and down the dilution scale.
4.8. In vitro anti-fungal activity
In vitro anti-fungal activity of the compounds were evaluated
on a panel of three ATCC strains (Candida albicans ATCC
44859 (CA1); Candida albicans ATCC 90028 (CA2); Candida
krusei ATCC 6258 (CK1)) and eight clinical yeast isolates
(Candida krusei E28 (CK2); Candida tropicalis 156 (CT);
Candida glabrata 20/I (CG); Candida lusitaniae 2446/I (CL);
Trichosporon asahii 1188 (TA)) and filamentous fungi
(Aspergillus fumigatus 231 (AF); Absidia corymbifera 272 (AC);
Trichophyton mentagrophytes 445 (TM)) from the collection of
fungal strains deposited at the Department of Biological and
Medical Sciences, Faculty of Pharmacy, Charles University,
Hradec Králové, Czech Republic. Three ATCC strains were used
as the quality control strains. All of the isolates were main-
tained on Sabouraud dextrose agar prior to being tested.
Minimum inhibitory concentrations (MICs) were deter-
mined by modified CLSI standard of microdilution format of
the M27-A3 and M38-A2 documents.35 DMSO (100%) served as
a diluent for all compounds; the final concentration did not
exceed 2%. RPMI-1640 (Sevapharma, Prague) medium sup-
plemented with L-glutamine and buffered with 0.165 M mor-
pholinepropanesulfonic acid (Serva) to pH 7.0 by 10 M NaOH
was used as the test medium. The wells of the microdilution
tray contained 200 µL of the RPMI-1640 medium with 2-fold
serial dilutions of the compounds (1000–0.244 µmol L−1 for
the new compounds) and 10 µL of inoculum suspension.
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Fungal inoculum in RPMI-1640 was prepared to give a final
concentration of 5 × 103 ± 0.2 CFU mL−1. The trays were incu-
bated at 308 K, and MICs were read visually after 24 and 48 h.
The MIC values for the dermatophytic strain (T. mentagro-
phytes) were determined after 72 and 120 h. The MICs were
defined as 80% inhibition (IC80) of the control growth for
yeasts and as 50% inhibition (IC50) of the control growth for
filamentous fungi. MICs were determined twice and in dupli-
cate. The deviations from the usually obtained values were no
higher than the nearest concentration value up and down the
dilution scale.
Abbreviations
AC Absidia corymbifera 272
AF Aspergillus fumigatus 231
bp Base pair
CA1 Candida albicans ATCC 44859
CA2 Candida albicans ATCC 90028
CFU Colony-forming unit
CG Candida glabrata 20/I
Cip Ciprofloxacin
CipA Ciprofloxacin analogue i.e. 7-(4-(decanoyl)
piperazin-1-yl) derivative of Cip
CipA-H Deprotonated ciprofloxacin analogue
CK1 Candida krusei ATCC 6258
CK2 Candida krusei E28
CL Candida lusitaniae 2446/I
CP Candida parapsilosis ATCC 22019
CT Candida tropicalis 156










dsDNA Double strand DNA




ESI-MS Electrospray ionisation mass spectrometry
EtBr Ethidium bromide
G. mellonella Galleria mellonella
HEPES 2-[4-(2-Hydroxyethyl)piperazin-1-yl]ethane-
sulfonic acid
Hpr-norf N-Propyl protected form of norfloxacin
IR Infra-red
J Coupling constant
K. pneumoniae Klebsiella pneumoniae
KP Klebsiella pneumoniae
KP-E Klebsiella pneumoniae ESBL positive
m/z Mass to charge ratio
MH Mueller-Hinton
MIC Minimum inhibitory concentration
Moxi Moxifloxacin
MRSA Methicillin resistant Staphylococcus aureus
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide





ROS Reactive oxygen species
RPMI-1640 Roswell Park Memorial Institute medium
S. aureus Staphylococcus aureus
SA Staphylococcus aureus
SE Staphylococcus epidermidis
stDNA salmon testes DNA





TM Trichophyton mentagrophytes 445
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